Aeon biopharma presents positive results from phase 2 clinical trial of abp-450 (prabotulinumtoxina) in cervical dystonia at the international parkinson and movement disorders society congress®

Irvine, calif., aug. 29, 2023 (globe newswire) -- aeon biopharma, inc. (“aeon” or the “company”) (nyse: aeon, aeon ws), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced the presentation of positive results from its phase 2 clinical study of abp-450 for the treatment of cervical dystonia (cd), a chronic and debilitating neurologic condition affecting the muscles of the neck, at the international parkinson and movement disorders society congress® (ip-mds), which is being held at the bella center in copenhagen, denmark, from august 27 – 31, 2023. the data was previously released by the company in september 2022.
AEON Ratings Summary
AEON Quant Ranking